Legend Biotech's Manufacturing Expansion Could Be Masking a Demand Problem for CARVYKTI

Legend Biotech Corporation (LEGN) reports first-quarter 2026 earnings before the market opens on May 12, 2026, with analysts expecting the company to approach breakeven as its CAR-T therapy Carvykti continues its commercial ramp. The central question is whether Legend can sustain its revenue momentum while narrowing losses toward profitability, a critical inflection point for this commercial-stage biotech. With analyst sentiment unchanged but price targets implying substantial upside, the release will test whether the company's execution can justify the Street's optimism.

Part 1: Earnings Preview

Legend Biotech is a commercial-stage biopharmaceutical company specializing in chimeric antigen receptor T-cell (CAR-T) therapies for oncology, with its lead asset Carvykti approved for relapsed or refractory multiple myeloma. Headquartered in Somerset, New Jersey, the company operates through a strategic partnership with Janssen Biotech, a Johnson & Johnson subsidiary, to commercialize its innovative cellular therapies globally.

Legend is scheduled to report first-quarter 2026 results before the market opens on May 12, 2026. Analysts expect an EPS of -$0.02 on revenue of approximately $313 million. The company most recently reported fourth-quarter 2025 EPS of -$0.08, which beat estimates by 52.94%. Compared to the same quarter last year (Q1 2025), when Legend posted -$0.07 per share, the current estimate represents a 71.43% improvement, signaling continued progress toward profitability.

Three key themes define this earnings story:

Carvykti Commercial Momentum: Revenue growth remains the dominant narrative, with analysts projecting $313 million for the quarter—a 60.56% increase year-over-year. The therapy's uptake in multiple myeloma continues to drive top-line expansion, and investors will scrutinize whether Legend can maintain this trajectory as competition intensifies in the CAR-T space.

Path to Profitability: With consensus estimates approaching breakeven for Q1 and projecting positive earnings of $0.31 for full-year 2026, the company stands at a critical inflection point. The Street is watching whether operational leverage from rising sales can offset manufacturing and commercialization costs, particularly as Legend scales production capacity.

Regulatory and Pipeline Developments: Beyond Carvykti's commercial performance, investors are focused on potential label expansions and pipeline progress. Any updates on earlier-line indications or new CAR-T candidates could significantly impact the growth narrative and justify the substantial analyst price targets.

Ahead of the release, Wall Street maintains a bullish stance. The consensus rating of 4.29 reflects strong conviction, with 10 analysts issuing Strong Buy recommendations. The average price target of $60.65 implies significant upside from current levels, though recent estimate revisions have trended downward—the prior Q1 estimate of -$0.07 has improved to -$0.02, while full-year 2026 expectations have risen from -$0.81 to $0.31, indicating growing confidence in the company's financial trajectory.

Part 2: Historical Earnings Performance

Legend Biotech has demonstrated a mixed but improving earnings track record over the past four quarters. The company beat estimates in three of the last four releases, with surprises of +82.50% in Q1 2025, +15.38% in Q3 2025, and +52.94% in Q4 2025. The sole miss came in Q2 2025, when the company reported -$0.34 versus expectations of -$0.22, a -54.55% shortfall.

The trend shows meaningful progress toward profitability. Reported losses have narrowed sequentially from -$0.34 in Q2 2025 to -$0.11 in Q3 2025 and -$0.08 in Q4 2025, reflecting improving operational efficiency as revenue scales. The magnitude of beats has been substantial when they occur—the Q1 2025 surprise of 82.50% and Q4 2025's 52.94% beat suggest the company is consistently outperforming conservative Street expectations.

This pattern of beats, combined with steadily narrowing losses, indicates Legend is executing well on its commercialization strategy. The Q2 2025 miss appears to be an outlier in an otherwise positive trajectory, and the company has since returned to form with consecutive beats. Investors should note that estimates have been rising throughout this period, yet Legend continues to exceed them, a bullish signal heading into the Q1 2026 release.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Legend Biotech typically reports earnings before the market opens, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.

Historical price action around Legend's earnings releases shows significant volatility, with an average absolute Day 0 move of 2.87% and Day +1 move of 3.20%. The stock has exhibited wide intraday ranges, averaging 8.81% on Day 0 and 5.97% on Day +1, reflecting the biotech's inherent volatility and investor sensitivity to quarterly results.

The direction of moves has been mixed but recently more positive. The most recent release on March 10, 2026, saw the stock gain 2.19% on Day 0 and 3.63% on Day +1. However, the May 2025 release triggered a sharp 10.55% decline on Day +1, demonstrating the stock's capacity for outsized moves in either direction. The largest single-day reaction came in March 2025, when the stock surged 9.29% on Day 0 following a strong earnings beat.

Investors should prepare for meaningful volatility, with historical data suggesting moves in the 3-10% range are common. The stock's recent tendency to rally on beats and the improving fundamental trajectory suggest positive surprises could drive upside, though the biotech's volatility profile means downside risk remains substantial if results disappoint.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 8.14% through the May 15 expiration, which aligns closely with the stock's average historical Day 0 range of 8.81% but exceeds the average absolute Day 0 move of 2.87%. This suggests options traders are anticipating volatility consistent with Legend's typical earnings behavior, though the implied move sits at the higher end of recent single-day reactions, indicating heightened uncertainty around this release.

Part 3: What Analysts Are Saying

Analysts maintain a bullish stance on Legend Biotech, with a consensus rating of 4.29 and an average price target of $60.65—representing 137% upside from the current price of $25.58. The Street's conviction is evident in the rating breakdown: 10 Strong Buys, 2 Moderate Buys, and 5 Holds, with no sell ratings. The price target range spans from a low of $21.00 to a high of $120.00, reflecting divergent views on the company's long-term potential.

Analyst sentiment has remained unchanged over the past month, with rating counts and the average recommendation holding steady at 4.29. This stability suggests the Street is maintaining its positive outlook despite recent stock price volatility, viewing the current levels as an opportunity rather than a reason to downgrade. The lack of negative revisions indicates analysts are comfortable with Legend's execution and growth trajectory heading into the Q1 release.

The consensus price target of $60.65 implies substantial upside and reflects optimism about Carvykti's commercial potential and Legend's path to profitability. However, the wide target range—from $21.00 to $120.00—underscores the uncertainty inherent in biotech investing, where outcomes can vary dramatically based on regulatory developments, competitive dynamics, and commercial execution. The clustering of Strong Buy ratings suggests most analysts believe the risk-reward profile favors the upside, particularly as the company approaches breakeven and full-year 2026 profitability estimates turn positive.

Part 4: Technical Picture

Legend Biotech enters earnings with improving technical momentum after a volatile period. The Barchart Technical Opinion currently shows a Buy signal at 24%, up sharply from 8% Buy last week but down significantly from 80% Sell a month ago. This rapid shift reflects the stock's recent recovery from oversold conditions, though the signal strength remains weak.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum has turned positive as the stock rebounds from recent lows
• Medium-term (Hold): Neutral reading suggests the intermediate trend remains in consolidation as the stock works through resistance levels
• Long-term (Hold): Neutral longer-term signal reflects the stock's struggle to establish a sustained uptrend above key moving averages

Trend Characteristics: The weak strength and weakest direction classification indicate the stock remains in a fragile technical position despite recent improvement, suggesting earnings results will be critical in determining whether the nascent recovery can gain traction or if the stock reverts to its recent downtrend.

The stock is trading at $25.58, positioned above its 20-day ($24.44), 50-day ($20.73), and 100-day ($20.42) moving averages, but below its 5-day ($27.95), 10-day ($25.97), and 200-day ($26.59) moving averages. This mixed picture shows the stock has bounced from its 50-day support but faces resistance at the 200-day moving average, a key long-term trend indicator.

The 200-day moving average at $26.59 represents immediate overhead resistance, while the 50-day at $20.73 provides support on any pullback. The stock's position between these levels creates a neutral setup heading into earnings—a strong beat could propel the stock through the 200-day resistance and trigger a sustained rally, while a disappointment could send it back toward the 50-day support. The weak technical strength and recent volatility suggest traders should prepare for significant post-earnings movement, with the options market's 8.14% expected move providing a reasonable guide for potential price swings.